You are here: Industry Insights > COVID-19 vaccine

News List

BREAKING NEWS: Researchers may know the cause for COVID-19 vaccine related blood clots europeanpharmaceuticalreview
May 31, 2021
Investigators at the Goethe University of Frankfurt believe that post-transcriptional modifications may be causing the clotting problems associated with recombinant vector COVID-19 vaccines.
EU authorises Pfizer-BioNTech Covid-19 vaccine in adolescents pharmaceutical-technology
May 31, 2021
Pfizer and BioNTech have received expanded Conditional Marketing Authorization (CMA) in the European Union (EU) for their Covid-19 vaccine, Comirnaty, to include people aged 12 to 15 years.
Significant adverse effect unlikely with doses of different COVID-19 vaccines, but further scrutiny required: Govt expresspharma
May 31, 2021
Any significant adverse effect is unlikely if the second dose of a different COVID-19 vaccine is administered, but reaching a firm opinion on this will need more scrutiny and understanding, the Centre said.
RDIF, UNICEF sign  agreement for supply of 220 million doses of Sputnik V vaccine expresspharma
May 31, 2021
Concurrently, RDIF will be holding a separate discussion with Gavi, the Vaccine Alliance to see the Sputnik V vaccine considered for inclusion in the COVAX Facility’s Portfolio of COVID-19 vaccines.
Study reveals new DNA vaccine for COVID-19 effective in mice, hamsters expresspharma
May 31, 2021
DNA vaccines can often be produced more quickly and at lower cost, and transported without the requirement of cold temperatures, the researchers said.
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate worldpharmanews
May 28, 2021
Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate.
Africa urgently needs 20 million second doses of COVID-19 vaccine worldpharmanews
May 28, 2021
Africa needs at least 20 million doses of the Oxford-AstraZeneca vaccine in the next six weeks to get second doses to all who received a first dose within the 8 - 12-week interval between doses recommended by the World Health Organization (WHO).
Moderna’s COVID-19 vaccine 93 percent effective in adolescents europeanpharmaceuticalreview
May 28, 2021
New Phase II/III study data shows Moderna’s COVID-19 vaccine is safe and immunogenic in patients aged 12 to less than 18 years old.
First patient dosed with multi-variant second-generation COVID-19 vaccine europeanpharmaceuticalreview
May 28, 2021
The first-in-human trial of OSE Immunotherapeutics’ multi-variant, second-generation COVID-19 vaccine has enrolled and dosed its first participant.
Pfizer Explors Coadministration of Its 20-valent Pneumococcal Vaccine With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine americanpharmaceuticalreview
May 28, 2021
Pfizer announced that the first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 116 117 Next page